Press

Nucleus, a Data-Driven Psychedelics Platform, Begins to Orbit the Mental Health Crisis; Logan Lenz to Captain the Ship

Jan 19 • 4 min read

Nucleus, a South Florida startup focused on mental health data and technologies, today announced its launch. The company, which is wholly owned by the venture capital firm, Iter Investments, is unveiling an entire ecosystem designed to meet people where they are and support them on their mental health journey. The platform is centered around a unique search…

Survey Finds Majority of Affected Americans Approve of Psychedelics as an Alternative Treatment to Address Anxiety, Depression and PTSD

Jan 19 • 4 min read

A new survey conducted by The Harris Poll on behalf of Delic Holdings Corp (CSE: DELC) (OTCQB: DELCF) (Original Source), a leader in new medicines and treatments for a modern world, reports that nearly two thirds of Americans who suffer from anxiety/depression/PTSD (65%) believe that psychedelic medicine (i.e. ketamine, psilocybin and MDMA) should be made available to patients…

MYND Life Sciences Announces Collaborative Research Agreement with the University of British Columbia

Jan 14 • 3 min read

MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced that it has entered into Collaborative Research Agreement (the “Agreement”) with the University of British Columbia (“UBC”) focussing on Novel Therapies for Neurological Diseases. MYND is creating safe and effective precision medicines…

Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients

Jan 13 • 5 min read

Mydecine Innovations Group (NEO: MYCO), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, announced today they would be launching The Special Access Support and Supply Program (SASSP) to provide products and services to physicians, clinics, and hospitals in Canada who are looking to treat patients through…

atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program

Jan 12 • 5 min read

atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the U.S. Food and Drug Administration (FDA) has given Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R-ketamine). atai plans to initiate the study early this year through its…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435